Highest-materiality recent filing
Panacea Life Sciences signs licensing deal with Sky Wellness for CBD product sales and development
Revenue split: 40% net revenue to Panacea, 60% to Sky Wellness for existing CBD inventory.
Panacea Life Sciences dismisses BF Borgers as auditor after SEC ban; no replacement
Dismissed BF Borgers CPA PC as independent auditor effective May 6, 2024, following SEC order barring BF Borgers from public practice.
Panacea Life Sciences issues 666K shares to settle $100K note payment
Converted $100,000 note payment to 666,000 shares of common stock on March 5, 2024.
Panacea Life sells PUR Life assets to related party PLM Holdings for $180K note
PLM Holdings (controlled by Panacea CEO and president) acquires all PUR Life assets and assumes related franchise liabilities.
Panacea Life Sciences Holdings files N7 Enterprises financials showing losses and going concern
N7 had $326k revenue and $82k net loss in 2022; 6mo2023 revenue $1.18M, net loss $147k.
Panacea Life Sciences acquires 8 Nitro Kava retail stores for 78,530 Series N-7 Preferred shares
Acquired 8 Nitro Kava retail stores and a distribution center in Tampa, FL from N7 Enterprises sellers.
Panacea Life Sciences acquires PUR Life Medical franchise for $1M cash plus up to $1.6M contingent
Purchase price of $1M cash plus up to $1.6M payable over 4 years based on franchise fee and royalty collection.
Panacea Life Sciences to acquire eight Nitro Kava stores in Tampa for convertible preferred shares
Acquisition of 8 retail locations, distribution facilities, warehouse in Tampa area for 84,548 Series E convertible preferred shares.
Panacea grants 1.11M shares to CEO, President, Board member, Controller in lieu of cash compensation
Leslie Buttorff (CEO) receives 760,000 shares for her 2023 annual salary.
Panacea Life Sciences agrees to repay $385K convertible note via cash and equity conversion
Company to pay $135,000 funded under CEO line of credit on Feb 13, 2023; $100,000 by June 30, 2023.
Panacea Life Sciences signs LOI to acquire N7 Enterprises for 22.2M shares
Panacea will issue 22.2 million common shares to N7 Enterprises stockholders.
Panacea repays $1.11M convertible note; CEO credit line raised to $5M
Repaid $1,110,306.85 on Dec 21, 2022 to retire a 10% OID senior convertible note issued Nov 2021.
Dr. Janice Nerger resigns from Panacea Life Sciences board effective July 21, 2022
Dr. Janice Nerger resigned from the board effective July 21, 2022, to accept interim provost role at Colorado State University.
Presentation made on June 8, 2022 by CEO Leslie Buttorff to investment community.
CEO Leslie Buttorff presented to investors on May 3, 2022; no specifics disclosed
CEO Leslie Buttorff made a presentation to certain members of the investment community on May 3, 2022.
Panacea exchanges 350 Series A shares for $385K convertible note & warrants
Issued $385K 10% OID senior convertible note due March 2023, convertible at $1.40/sh.
Panacea Life Sciences dismisses auditor RBSM, appoints BF Borgers as new independent accountant
Dismissed RBSM LLP as independent auditor effective December 28, 2021.
Board concluded Q3 2021 unaudited financials filed Nov 22 should no longer be relied upon due to errors in revenue, cost of goods sold, lease liability, options and warrants.
Panacea Life Sciences 2020 revenue $9.0M, net loss $5.2M; auditor raises going concern
Revenue $9.0M in 2020 vs $2.2M in 2019; net loss $5.2M vs $2.8M.
Panacea Life Sciences closes $1M private placement on Nov 30, 2021
Closed private placement previously announced on Nov 24, 2021; received $1,000,000 wire.
Panacea Life Sciences secures $1M via convertible note and warrant sale to Lincoln Park Capital
Sold $1.1M senior convertible note (net $1M) and warrants for 785,715 shares at $1.40 to Lincoln Park Capital Fund.
Company changed name to Panacea Life Sciences Holdings, Inc., effective Oct 25, 2021.
Exactus adds Dr. Janice Nerger to board of directors
Dr. Janice Nerger officially became a director on October 17, 2021.
Exactus restates Q2 2021 financials; related-party revenue of $4.7M improperly recognized
Board concluded Q2 2021 Form 10-Q cannot be relied upon due to material errors.
Exactus CEO Leslie Buttorff delivers investor presentation; no material details disclosed
CEO Leslie Buttorff presented to investment community on July 8, 2021.
Exactus acquires Panacea Life Sciences; Leslie Buttorff becomes CEO
Exactus issues 473.6M common shares + preferred stock to acquire Panacea; Buttorff owns ~61% fully diluted.
On July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors of Panacea Life Sciences Holdings, Inc., effective immediately.
On October 17, 2021, following Exactus, Inc. (the “Company”) compliance with Rule 14f-1 under the Securities Exchange Act of 1934, Dr. Janice Nerger officially became a director of the Company.
John Price, a director (who had not held any officer positions with the Company), previously resigned from as a director of the Company.
Leslie Buttorff was appointed director.
Mr. Wert previously was Executive Chairman but resigned from that role.
On June 30, 2021, Julian Pittam resigned as director of the Company
Max materiality 0.95 · Median 0.60 · Most common event other_material